Evidence map›Paper›PMID 34323141›Full record

ArticleTechnology in cancer research & treatment

Research Progress of MicroRNA in Chemotherapy Resistance of Osteosarcoma.

Zhaopeng Tang, Yubao Lu, Yutong Chen, Jiarui Zhang, Zhijun Chen, Qianfeng Wang

Open access · goldAbstract read
In one paragraph

Article in Technology in cancer research & treatment. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
1.1field-weighted citation impact, top 25% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 14 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Review
  5. Article
  6. Review
  7. Review
  8. Research Progress of Exosome-Loaded miRNA in Osteosarcoma.Cancer control : journal of the Moffitt Cancer Center
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 4 institutions in 1 country.

Zhaopeng TangDepartment of Orthopaedics, 586778Gansu Provincial Hospital of Traditional Chinese Medicine, Lanzhou, Gansu, China.
Yubao LuThe Second Clinical Medical College, 12426Lanzhou University, Lanzhou, Gansu, China.ORCID 0000-0003-4375-8316
Yutong ChenThe Second Clinical Medical College, 12426Lanzhou University, Lanzhou, Gansu, China.
Jiarui ZhangThe First Clinical Medical College, 12426Lanzhou University, Lanzhou, Gansu, China.
Zhijun ChenThe First Clinical Medical College, 12426Lanzhou University, Lanzhou, Gansu, China.
Qianfeng WangDepartment of Gastroenterology, Gansu Provincial People's Hospital, Lanzhou, Gansu, China.
Gansu Provincial Hospital · CNLanzhou University · CNLanzhou University Second Hospital · CNSun Yat-sen University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Osteosarcoma (OS) is a malignant tumor prevalent in adolescents; however, a clinically effective treatment for this malignancy is lacking. The lack of effective treatment methods and factors, such as recurrence and drug resistance, further dampen the prospect of clinically treating OS. In recent years, small molecule microRNAs (miRNAs) with a length of approximately 20-24 nucleotides have gradually attracted the attention of the medical community. Studies have found that miRNAs can regulate the cell cycle, apoptosis, cell proliferation, and cell proliferation. The metabolic response of cancer cells, invasion and metastasis of cancer cells, and angiogenesis play an important role in the process of tumorigenesis. miRNAs regulate gene expression by regulating mRNA expression after transcription. A large amount of data from many studies indicate that they have diagnostic and prognostic biomarker effects in OS and are involved in regulating the metabolism of cancer cells and resistance or sensitivity to chemotherapy drugs. Chemotherapy resistance is one of the most critical problems in clinically treating OS. A large number of basic studies and systematic summaries are required to provide a theoretical basis for elucidating the mechanism and drug development of chemotherapeutic agents. Therefore, this article discusses the role of miRNAs in OS resistance. Herein, the related research progress of the studies is reviewed to provide more useful information for the development of effective therapy.

Indexed as

Gene Expression Regulation, NeoplasticAntineoplastic AgentsAutophagyBiomarkers, TumorBone NeoplasmsCell Line, TumorDrug Resistance, MultipleDrug Resistance, NeoplasmHumansMicroRNAsOsteosarcomaPrognosisSignal TransductionAntineoplastic AgentsBiomarkers, TumorMicroRNAschemotherapeutic drugsdrug resistancemalignantmicroRNAosteosarcomaprognostic marker

Identifiers

PMID34323141
PMCPMC8326994
OpenAlexW3185152545

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.